title: Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer.
abstract: We have investigated the action of recombinant human gamma-interferon (rHuIFN-gamma) against human ovarian cancer xenografts growing as ascites or as bulky solid i.p. tumors in nude mice. Both forms of the disease responded to i.p. rHuIFN-gamma with significant increases in mouse survival time, and in 2 of 3 ascitic models the mice were cured of peritoneal disease. The activity of rHuIFN-gamma was dose and schedule dependent, and xenografts derived from 3 different patients showed a heterogeneity of response. Peak i.p. levels of rHuIFN-gamma in nude mice bearing multiple i.p. solid tumors were similar to those found in ovarian cancer patients receiving i.p. rHuIFN-gamma, but clearance was more rapid in the mice. Rat gamma-interferon had no antitumor activity at the same doses and schedules although it had some biological activity in the nude mice. Histological examination of treated tumors revealed increased necrosis and loss of cellular organization with large areas of hypocellular epithelial mucin. These changes were preceded by a fall in tumor tryptophan and a rise in tumor kynurenine. We conclude that rHuIFN-gamma has a direct dose related antitumor effect on ovarian cancer xenografts that is preceded by increased metabolism of tryptophan.
authors.affiliation: Imperial Cancer Research Fund, Lincoln's Inn Fields, London, United Kingdom.
authors.forename: S T
authors.initials: ST
authors.lastname: Malik
authors.forename: R G
authors.initials: RG
authors.lastname: Knowles
authors.forename: N
authors.initials: N
authors.lastname: East
authors.forename: D
authors.initials: D
authors.lastname: Lando
authors.forename: G
authors.initials: G
authors.lastname: Stamp
authors.forename: F R
authors.initials: FR
authors.lastname: Balkwill
mesh_terms: D000818:Animals; D001201:Ascites; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011994:Recombinant Proteins; D013045:Species Specificity; D016019:Survival Analysis; D014183:Transplantation, Heterologous; D014364:Tryptophan / Q000378:metabolism
chemical_list: D011994:Recombinant Proteins; D007371:Interferon-gamma; D014364:Tryptophan